Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
sanofi-aventis Group
Data demonstrates greater flexibility with mealtime dosing of Apidra
July 6th, 2005
The sanofi-aventis Group announced the results of a subanalysis of a study demonstrating that its prandial insulin, Apidra (insulin glulisine [rDNA origin] injection), when administered before, during, or after meals, produced comparable glycemic control (as measured by reductions in A1C levels) as premeal administration of regular human insulin in the treatment of patients with type 1 diabetes. These findings were presented at the American Diabetes Association's 65th annual scientific session in San Diego, California "There have been few studies examining the practice of postmeal prandial insulin administration, but because we know that many people...
Source: Biotech Week (2005-07-06)
|
